Bayer Presents Dozens of Innovations at 8th CIIE

Bayer, a global leader in life sciences, is participating in the China International Import Expo (CIIE) for the eighth consecutive year, with the company's mission of "Health for All, Hunger for None."

At the two booths with a total area of 800 square meters, Bayer is showcasing innovative products and solutions in the fields of health care and agriculture from its three business divisions – pharmaceuticals (and radiology), consumer health and crop science.

Through immersive interactive experiences and deepening local collaborations, Bayer is fully demonstrating its commitment to seizing opportunities in China, deepening its presence in the Chinese market with multi-dimensional innovations, and embarking on a new journey of high-quality development with China.

Bill Anderson, chairman of the Board of Management of Bayer AG, said, "We're proud to be here for the eighth year in a row, collaborating with our partners to explore bold ideas and create shared value. The 8th CIIE is more than a tradition – it's an opportunity to showcase how we're working to address the needs of the people we serve in China and around the world."

"We're highlighting solutions that aim to improve lives, support farmers, and advance health outcomes for patients. Our commitment goes beyond products. We're focused on fostering partnerships that drive innovation and create value for the communities we serve, and the possibilities that emerge from working together are limitless. And we're excited to explore them with you at this year's CIIE."

The exhibition experience takes on a fresh look with its newly upgraded brand visual system. The innovative dome structure at the top of the booth symbolizes Bayer's dual-drive approach, combining global vision with local engagement, to safeguard public health and better life while building a sustainable future.

Through its immersive booth design and diverse educational activities, it offers visitors a tangible experience of cutting-edge innovations, vividly conveying the value delivered to patients, consumers and growers.

A total of 26 exhibits are featured, ranging from breakthrough drugs and therapies in Pharmaceuticals to trusted self-care solutions in Consumer Health and modern agricultural innovations in Crop Science, reflecting how Bayer's innovation deeply integrates with the implementation of China's strategic national initiatives.

In pharmaceuticals, the Eylea 8mg, which makes its CIIE debut after recent approval in China, is indicated for the treatment of age-related diseases – neovascular (wet) age-related macular degeneration (nAMD).

Other innovative treatment options cover therapeutic areas such as non-small cell lung cancer, moderate-to-severe vasomotor symptoms (VMS) associated with menopause or induced by adjuvant endocrine therapy for breast cancer, hormone-sensitive prostate cancer (mHSPC) and heart failure.

In radiology, the MEDRAD Stellant D-CE high-pressure injection system and accessories represent a key milestone in Bayer's localization strategy. It was first exhibited in 2021 with an import certificate, and it gained approval for localized production in June of this year.

As for consumer health, five new offerings are making their global debuts, including locally formulated Bepanthen Nappy Rash Ointment, as well as Clarityne Mometasone Furoate Aqueous Nasal Spray, Talcid Lactulose Oral Solution, One A Day High EPA Fish Oil, and Elevit Kids Calcium, covering diverse self-care areas in allergy, digestive health, cardiovascular health and nutrition.

In Crop Science, it continues to leverage its global R&D capability and German quality standards and showcases De Lai, a crop performance enhancers brand launched in 2025, along with two flagship products, make their debut at the expo. The new corn seed brand Nong Bei Le, along with two new varieties tailored to the agricultural conditions of the Huang-Huai-Hai region, is also exhibited in this area.

Through CIIE, Bayer is broadening and deepening strategic collaborations with local partners to upgrade its engagement model from technology introduction to co-creation, ultimately sharing the Chinese innovation fruits with the globe.

The latest progress of Bayer Co.Lab and the Bayer E-Town Open Innovation Center is demonstrating its practice of collaborating with partners to build an open innovation platform and ecosystem through the "dual innovation engines" in China.

It's also leveraging the CIIE as an open cooperation platform to advance the Women's Health Ecosystem. Under the theme "Expanding the Ecosystem, Empowering Her Era," Bayer is deepening and expanding this initiative through collaborations with the United Nations Population Fund (UNFPA), JD.com, Alibaba and other institutions.

Through the China Center of Innovation and Partnership (CCIP), Bayer keeps up with the latest trends and changes in the industry and works together with other companies and research organizations to create new ideas and solutions. It reaches a series of agreements with partners during the expo, spanning cutting-edge research, product innovation, and health accessibility initiatives.

In Crop Science, in the area of innovative service models, the Better Life Farming (BLF) Program was launched in 2024, empowering retailers through an innovative business model to better serve smallholder farmers and bridge the "last mile" to achieving higher yields. The program now covers over 150 BLF centers nationwide in 2025.

Bayer has reaffirmed its commitment to China, aligned with the strategic goals of Healthy China and a strong agricultural sector, working with partners to build robust bridges of open cooperation, and moving with the times to drive high-quality development through sustained innovation.

Looking ahead, Bayer pledges to deepen its commitment and leverage cutting-edge innovation to join hands with China on this new journey to chart a course for shared prosperity and contribute to an open global economy.